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 Abstract
Objective: Elevated levels of high-density lipoprotein (HDL) cholesterol are inversely related to the risk of cardiovascular disease. The anti-
atherosclerotic function of HDL is mainly ascribed to its role in reverse cholesterol transport, and requires the integrity of HDL structure.
Experimental evidence suggests that the ability of HDL to promote removal of excess cholesterol from peripheral cells is impaired upon
oxidation. On the other hand, tyrosylation of HDL enhances its protective function, suggesting that not all forms of modified lipoprotein may
be atherogenic. In the present study we investigated the effect of a mild oxidation of HDL3 on its function as cholesterol acceptor.
Methods and results: A mild oxidative stress (induced by 15 min exposure of HDL3 to 1 μM Cu
++ or to 15-lipoxygenase) caused the
formation of pre-β-migrating particles. Compared to native lipoprotein, mildly modified HDL3 induced a significant ATP-binding cassette
transporter 1 (ABCA1)-mediated increase of cholesterol and phospholipids efflux from J774 macrophages. This effect was abolished by an
inhibitor of ABCA1-mediated lipid efflux (glyburide) and was absent in Tangier fibroblasts.
Conclusions: A mild oxidative modification of HDL3 may improve its function as cholesterol acceptor, increasing ABCA1-mediated lipid
efflux from macrophages, a process that may reduce foam cell formation.
© 2007 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.Keywords: High-density lipoprotein; Reverse cholesterol transport; Oxidative stress; 15-lipoxygenase; pre-β-HDL; ATP-binding cassette transporter 11. Introduction
A number of studies have established that elevated
concentrations of plasma high-density lipoprotein (HDL)
reduce the risk for coronary heart disease (CHD) [1–3]. The
atheroprotective role of HDL is believed to depend mainly
upon its ability to remove cholesterol from peripheral cells, a
process known as reverse cholesterol transport [4,5].
Human HDL consists of distinct subfractions that, besides
differences in shape, density, size, and charge, differ in the
mechanisms bywhich they promote the removal of cholesterol
from cells [6,7]. Among the HDL subfractions, pre-β1-HDL,⁎ Corresponding author. Tel.: +39 02 50318293; fax: +39 02 50318386.
E-mail address: angela.pirillo@unimi.it (A. Pirillo).
0008-6363/$ - see front matter © 2007 European Society of Cardiology. Publish
doi:10.1016/j.cardiores.2007.04.021which contains apoA-I as only apoprotein and exhibits pre-β
electrophoretic mobility, appears to be the most efficient
acceptor of cellular cholesterol [7–9], via the interaction with
ATP-binding cassette transporter 1 (ABCA1) [10–12]. The
physiological mechanism by which pre-β1-HDL is generated
in plasma is not fully understood, but there are at least two
potential sources: i) it may be derived from the interaction of
lipid poor apoA-I secreted from liver or intestine with cell
membrane lipids [13,14]; ii) it may be formed during the
conversion of mature, spherical HDL (α-HDL) [15]. In vitro,
pre-β1-HDL can be formed following the interaction of free
apoA-I with cholesterol-loaded macrophages [16] or fibro-
blasts [17]. Furthermore, the concentration of pre-β1-HDL is
increased under pathophysiological conditions, such as
hypercholesterolemia [18], showing a positive correlationed by Elsevier B.V. All rights reserved.
Fig. 1. Mild modified HDL3 increased cholesterol efflux. J774 were labeled
with 3H-cholesterol as described in Methods, then incubated for 6 h with
10 μg/ml of native HDL3 or HDL3 modified with Cu
++ 1 μM or 15-LO for
15 min. Values are mean±SD of 6 independent experiments. ⁎pb0.0005 vs
native HDL3.
Fig. 2. Mild oxidative modification of HDL3 generated pre-β-migrating
particles. The distribution of apoA-I in HDL3 subclasses of native, Cu
++
1 μM or 15-LO-modified HDL3 was analyzed by 0.8% agarose gel
electrophoresis, followed by western blotting using an anti-apoA-I antibody.
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 with LDL concentration [19]; increased amounts of pre-β1-
HDL are also present in cholesterol-fed rabbits and mice [20].
The structural integrity of HDL is essential for their
function in the reverse cholesterol transport. In fact, severe
oxidation may impact the biological role of HDL by
impairing their ability to promote cholesterol efflux in vitro
[21–23]. There is growing pathophysiological evidence
that increased generation of reactive oxygen species and
oxidative stress participate in vivo to pro-atherogenic
mechanisms [24–26]. 15-lipoxygenase [27,28], an enzyme
that has been implicated in the conversion of native LDL
to an atherogenic form [28,29], may contribute to such
a mechanism. In a recent paper, we have shown that
15-lipoxygenase-mediated modification of HDL3 signif-
icantly reduces its role as efficient cholesterol acceptor
[30].
Data obtained with transgenic rabbits overexpressing
15-lipoxygenase [31,32], however, suggest also anti-
atherogenic effects for this enzyme [33]. In this work
we studied the functional effect of HDL exposure to a
mild oxidative stress, induced by low concentration of
copper ions or by 15-lipoxygenase for short periods.
These mild modifications caused a transient increase of
pre-β-migrating particles from α-HDL3, generating mod-
ified lipoprotein species which exhibited a significantly
improved capacity to stimulate reverse cholesterol trans-
port from macrophages.
2. Methods
2.1. Materials
MEM, DMEM, fetal bovine serum (FBS), bovine serum
albumin (BSA), 22R-OH cholesterol (22-OH), 9-cis-retinoic
acid (9cRA), glyburide and Oil red O were from Sigma (St.
Louis, MO, USA). 3H-cholesterol, methyl-3H-choline chlo-
ride, PD10 columns and ECL were from Amersham
Biosciences (Uppsala, Sweden). Antiserum anti-human
apoA-I was from Dade Behring (Marburg, Germany). SR-BIblocking antibody was fromAbcam (Cambridge, UK). Native
reticulocyte-type 15-LO was prepared as described [34].
Cholesterol kit was from Clonital, Italy.
2.2. Cell culture
J774 macrophages were cultured inMEM containing 10%
FBS; normal human skin fibroblast and Tangier fibroblasts
were cultured in DMEM supplemented with 10% FBS.
2.3. Isolation of plasma lipoproteins
The use of human material in this study conforms to the
principles outlined in the Declaration of Helsinki. LDL
(d=1.019–1.063 g/ml) and HDL3 (d=1.125–1.21 g/ml)
were isolated from fresh plasma of normolipidemic healthy
volunteers by sequential ultracentrifugation [35]. Protein
content was determined by the method of Lowry using BSA
as standard [36]. LDL were acetylated by repeated additions
of acetic anhydride [37].
2.4. Modification of HDL3
HDL3 (1 mg/ml) were modified by 15-lipoxygenase
(2 μl/ml) [30] or by CuSO4 1 μM for 15 min up to 24 h at
37 °C. The oxidation was blocked by the addition of 10 μM
BHT and by lowering the temperature to 4 °C. The TBARS
content and the apoproteins cross-linking in mildly modified
HDL3 were evaluated as previously described [30].
2.5. Agarose gel electrophoresis and western blotting
Aliquots of native and modified HDL3 were electrophor-
esed on a 0.8% agarose gel, then transferred onto a
nitrocellulose membrane. After blocking with 5% nonfat
milk in PBS-T (PBS-0.1% Tween) for 1 h at room
temperature, apoA-I was identified using an antiserum
anti-human apoA-I from rabbit (1:20000) followed by a
goat anti-rabbit IgG peroxidase-conjugated (1:20000).
Immuno-complexes were visualized using an ECL western
blotting detection system followed by autoradiography.
Fig. 4. Purification (A) and modification (B) of α-migrating particles. (A) α-
migrating particles were isolated from HDL3 by a discontinuous salt density
gradient (1.11–1.25 g/ml) and ultracentrifugation at 40,000 rpm at 5 °C for
18 h. The distribution of apoA-I in each fraction was determined by 0.8%
agarose gel electrophoresis and western blotting using an anti-human apoA-I
antiserum. (B) Fractions consisting of purified α-particles were modified
with Cu++ 1 μM, Cu++ 20 μM or 15-LO for the indicated times. After
modification, the distribution of apoA-I-containing particles was analysed
by 0.8% agarose gel electrophoresis and western blotting.
Fig. 3. Mild modified HDL3 increased ABCA1-mediated cholesterol (A)
and phospholipid (B) efflux and decreased total cholesterol content (C). J774
labeled with 3H-cholesterol (A) or methyl-3H-choline chloride (B) were pre-
incubated with 22-OH/9cRA (10 μM/1 μM), then incubated for 6 h (A) or
4 h (B) with 10 μg/ml of native HDL3 or HDL3 modified with Cu
++ 1 μM or
15-LO for 15 min. (C) Quantification of total cholesterol levels in lipid-
loaded macrophages after incubation with native or mildly modified HDL3.
Values are mean±SD from 6 (A) and 3 (B, C) independent experiments. (A)
⁎pb0.00005 vs native HDL3; (B) #pb0.05 vs native HDL3.
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 2.6. Cholesterol efflux experiments
J774 were labeled with 3H-cholesterol (1 μCi/ml) in
MEM containing 0.2% BSA and 50 μg/ml AcLDL; after
24 h, cells were washed once with PBS and incubated
for 24 h in MEM+0.2% BSA in the absence or the pre-
sence of 22-OH/9cRA (10 μM/1 μM). Labeling of
fibroblasts was carried out in DMEM containing 1% FBS
and 3H-cholesterol (1 μCi/ml); after 24 h cells, cells were
washed once with PBS and incubated for 24 h in DMEM
+0.2% BSA in the presence of 22-OH/9cRA (10 μM/1 μM).
To induce cholesterol efflux, 10 μg/ml of native HDL3 or
HDL3 modified with Cu
++ 1 μM or 15-LO for 15 min were
added to the cells for 6 h. At the end of the experiment, media
were collected, centrifuged to remove cellular debris and
aliquots were used to quantify the radioactivity content by
liquid scintillation. Cell monolayers were lysed in 0.1 NaOH
and aliquots were used to determine the intracellular radio-
activity content. The 3H-cholesterol release was calculatedas the ratio of radioactivity released in the medium to the
medium plus cell (total) radioactivity.
In some experiments, glyburide (1mM)was added together
with the lipoproteins to the medium; alternatively, cells were
pre-incubated with a SR-BI blocking antibody (1:1000
dilution) before the incubation with lipoproteins [30].
2.7. Phospholipid efflux experiments
J774 were incubated in MEM containing 0.2% BSA,
50 μg/ml AcLDL and methyl-3H-choline chloride (2 μCi/ml).
After 24 h, cells were washed with PBS and incubated for
24 h in MEM+0.2% BSA in the presence of 22-OH/9cRA
(10 μM/1 μM). Native HDL3 or HDL3 modified with Cu
++
1 μM or 15-LO for 15 min (10 μg/ml) were added to cells for
4 h. At the end of the experiment, media were collected,
centrifuged to remove cellular debris and lipids were extracted
with hexane:2-propanol (3:2). Radioactivity in the lipid
extracts was quantified by liquid scintillation. Cell monolayers
were lysed with 0.1N NaOH, lipids were extracted with
hexane:2-propanol and aliquots were used to determine the
intracellular radioactivity content.
2.8. Purification and modification of α-HDL3 particles
A discontinuous salt density gradient was created in an
ultracentrifuge tube. A solution containing 2 mg of HDL3
and 20 mg of BSA was adjusted to d=1.25 g/ml by the
addition of KBr. Two ml of the obtained solution was placed
in a Beckman ultracentrifuge tube and layered with: 2 ml of
d=1.21 g/ml, 2 ml of d=1.18 g/ml, 2 ml of d=1.16 g/ml,
1 ml of d=1.14 g/ml, 1 ml of d=1.12 g/ml and 2 ml of
Fig. 6. Glyburide inhibited ABCA1-mediated cholesterol efflux to mildly
modified HDL3. ABCA1 overexpressing J774 were incubated for 6 h with
10 μg/ml of native HDL3 or HDL3 modified for 15 min with Cu
++ 1 μM or
15-LO, in the absence or the presence of glyburide (1 mM) or a SR-BI
blocking antibody (1:1000). Values are mean±SD from 3 independent
experiments. ⁎pb0.005, ⁎⁎pb0.0005.
Fig. 7. Mildly modified HDL3 increased ABCA1-mediated cholesterol
efflux in normal fibroblast, but not in Tangier fibroblasts. Normal and
Tangier fibroblasts were labeled with 3H-cholesterol, pre-incubated with 22-
OH/9cRA (10 μM/1 μM), then incubated for 6 h with 10 μg/ml of native
HDL3 or HDL3 modified with Cu
++ 1 μM or 15-LO for 15 min. Values are
mean±SD from 3 independent experiments. ⁎pb0.05 vs native HDL3.
Fig. 5. Mild modified α-HDL3 increased ABCA1-mediated cholesterol
efflux. (A) J774 labeled with 3H-cholesterol were pre-incubated in the
absence or the presence of 22-OH/9cRA (10 μM/1 μM), then incubated for
6 h with 10 μg/ml of native α-HDL3 or α-HDL3 modified with Cu
++ 1 μMor
15-LO for 15 min. Values are mean±SD of 3 experiments performed in
duplicates. ⁎pb0.01 ⁎⁎pb0.005 vs native α-HDL3. (B) α-HDL3 were
modified with 15-LO for 15 min, then subjected to a density gradient
ultracentrifugation to remove pre-β-particles. Native, mildly modified or re-
isolated α-HDL3 (10 μg/ml) were the added to J774 overexpressing ABCA1
to evaluate cholesterol efflux. Values are mean±from 3 independent
experiments. 1: native α-HDL3; 2: α-HDL3 modified with 15-LO for
15 min; 3: α-particles reisolated from α-HDL3 modified with 15-LO for
15 min.
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 d=1.11 g/ml. Samples were centrifuged at 40,000 rpm at
5 °C for 18 h in a Beckman SW41 rotor. Twelve fractions
(1 ml each) were collected from the top of the tube. To study
the distribution of apoA-I in HDL3 particles, aliquots of
fractions obtained from the density gradient were subjected
to agarose gel electrophoresis and western blotting as
described above. Fractions consisting of purified α-particles
were retrieved, concentrated in a Centricon filter unit fitted
with a YM10 membrane and desalted in PBS using a
Sephadex G25 (PD10) column. The protein content was
evaluated by the Lowry method. α-HDL3 were modified
under the same experimental conditions described for HDL3.
After modification, the distribution of apoA-I-containing
particles was analyzed by agarose gel electrophoresis and
western blotting, as described.
For some experiments, after modification with 15-LO for
15 min, α-HDL3 were centrifuged in a density gradient to
remove new formed pre-β-particles, as described above.
2.9. Oil red O staining
Foam cell formation was induced by cholesterol-loading
with acetylated LDL (50 μg/ml) for 24 h; after this time, cellswere washed twice with PBS and incubated for 24 h with
100 μg/ml of HDL3 native ormodified for 15min with 15-LO.
At the end of the incubation, cells were fixed with 5%
paraformaldehyde for 1 h, then neutral lipids were stained with
Oil red O (0.2% in isopropanol) for 30 min. Cells were rinsed
thrice with water and the stained lipid droplets were visualized
by light microscopy. For quantification, the dye was extracted
in isopropanol and the absorbance was measured at 515 nm.
Cell protein concentration was determined by the method of
Lowry and absorbance values were normalized to protein.
2.10. Total cholesterol determination.
After cholesterol-loading with AcLDL (50 μg/ml), cells
were incubated for 24 h with 22-OH/9cRA (10 μM/1 μM)
to induce ABCA1 expression, then incubated for 6 h with
10 μg/ml HDL3 native or modified for 15 min with 15-LO.
Cellular lipids were extracted in hexane/isopropanol (3:2)
and cholesterol content was evaluated by a colorimetric assay
according to the instructions of the manufacturer and
570 A. Pirillo et al. / Cardiovascular Research 75 (2007) 566–574normalized by protein concentration, determined by the
method of Lowry.
3. Results
In agreement with our previous results [30], the
incubation of HDL3 with low concentrations of Cu
++
(1 μM) or with 15-LO for 15 min neither increased the
lipoprotein TBARS content, nor induced an appreciable
apolipoprotein cross-linking (data not shown). However,
compared to native lipoprotein, HDL3 modified for 15 min
with Cu++ 1 μM or 15-LO induced a higher cholesterol
efflux from J774 macrophages (Fig. 1). The increase was
independent of the modification type (chemical or enzymat-
ic) and, as expected from previous data [30], disappeared at
24 h. Analysis of HDL3 particles showed that incubation
with Cu++ 1 μMor 15-LO for 15 min induced the appearanceFig. 8. Mildly modified HDL3 decreased lipid content in J774. Lipid loaded J774 w
100 μg/ml of native HDL3 or HDL3 modified with 15-LO for 15′. Neutral lipids wer
light microscopy. Original magnification, 40×. (E) The dye was extracted with isop
corrected for cell protein concentrations. The data are expressed as percentage of lip
±SD from 3 independent experiments. ⁎pb0.01 vs native HDL3.of particles with pre-β electrophoretic mobility up to 2 h
modification (Fig. 2), undetectable at 24 h (Fig. 2).
We therefore addressed the question as to whether
the observed higher cholesterol efflux induced by mildly
modified HDL3 might be related to the increase of pre-β-
migrating particles, possibly through ABCA1 activity. To
this end, J774 cells were pre-incubated with 22-OH/9cRA to
increase ABCA1 expression [30,38]. Accordingly, these
cells exhibited a significantly higher cholesterol efflux when
incubated with mildly modified HDL3, compared with cells
incubated with native HDL3 (Fig. 3A). In agreement with
this finding, total cholesterol levels were lower in the
presence of mildly modified HDL3 (Fig. 3B).
ABCA1 is involved in the reverse cholesterol transport,
but also triggers the efflux of phospholipids to lipid poor
apoA-I [39]; for this reason, we studied the impact of mildly
modified HDL3 on this process: in cells overexpressingere incubated with 22-OH/9cRA (10 μM/1 μM), then incubated for 24 h with
e stained with Oil red O. (A–D) The stained lipid droplets were visualized by
ropanol and the absorbance was measured at 515 nm; the optical density was
id-loaded cells (AcLDL), set at 100% for each experiment. Values are mean
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 ABCA1 the incubation with HDL3 modified with Cu
++
1 μM or 15-LO for 15 min induced a significant increase in
phospholipid efflux compared to native HDL3 (Fig. 3C).
As native HDL3 did already contain a minor fraction
pre-β migrating particles (Fig. 2) whose amount was
increased after a mild oxidative modification, we aimed at
clarifying whether those particles were generated ex-novo
from α-particles or derived from a conformational
rearrangement of pre-β particles already present in native
lipoprotein. To this end, α-migrating particles were purified
from native HDL3 by density gradient ultracentrifugation
(Fig. 4A) and modified under the same experimental
conditions described for HDL3. In keeping with the data
with whole HDL3, short-term modification of α-HDL3 with
Cu++ 1 μM or 15-LO generated pre-β-migrating particles
up to 2 h, which disappeared at longer incubation periods
(Fig. 4B), indicating an ex-novo formation of the pre-β
particles after mild oxidative modification. A higher con-
centration of Cu++ (20 μM) failed to induce the formation
of pre-β particles from α-HDL3 (Fig. 4B). α-HDL3
modified with Cu++ 1 μM or 15-LO for 15 min induced,
when compared to native α-HDL3, a higher cholesterol
efflux from J774 cells under basal conditions (Fig. 5A). In
cells overexpressing ABCA1, mildly modified α-HDL3
further stimulated the cholesterol efflux process (Fig. 5A),
while no significant effect was found with native α-HDL3.
These data suggested that the newly formed pre-β-
migrating particles efficiently promoted cholesterol efflux
via an ABCA1-mediated mechanism; this finding was
further confirmed using as cholesterol acceptor isolated pre-
β-particles purified by density gradient ultracentrifugation
(data not shown).
On the other hand, the removal of pre-β-migrating
particles from α-HDL3 modified with 15-LO for 15 min
abolished the increased cholesterol efflux obtained with
mildly modified α-HDL3 (Fig. 5B), further indicating that
pre-β particles were responsible for the observed effect.
To show that ABCA1 activity was actually involved in
the increased cholesterol efflux observed with mildly
modified HDL3, J774 overexpressing ABCA1 were pre-
incubated with glyburide, an inhibitor of ABCA1-mediated
lipid efflux to apoA-I [40]. Glyburide reduced the cholesterol
efflux to native HDL3 by 36%, and to mild modified HDL3
by ∼70% (Fig. 6), indicating an essential contribution of
ABCA1 activity in the mildly modified HDL3-induced
cholesterol efflux. The presence of a SR-BI blocking
antibody, which reduces SR-BI-mediated cholesterol efflux
to α-HDL3 [30], could not inhibit cholesterol efflux to mildly
modified HDL3 (Fig. 6).
The most direct evidence that ABCA1 transporter is
involved in the increased cholesterol efflux induced by pre-β
HDL particles generated in mildly modified HDL3 was
obtained using Tangier fibroblasts as cellular model. These
cells do not express a functional ABCA1 transporter and
thus, the pre-β particles-induced cholesterol efflux is
predicted to be absent [41]. As expected, modification ofα-HDL3 with Cu
++ 1 μM or 15-LO for 15 min caused an
increase in cholesterol efflux from normal fibroblasts pre-
treated with 22-OH/9cRA to overexpress ABCA1 (Fig. 7).
In contrast, under the same experimental conditions, Tangier
fibroblasts did not show a stimulatory effect on cholesterol
release in the presence of mildly modified HDL3 (Fig. 7).
Finally, mildly modified HDL3 were tested for the ability
to reduce foam cell formation. After loading with AcLDL,
J774 exhibited extensive Oil red O staining (Fig. 8B, E)
compared to unloaded cells (Fig 8A). As expected, native
HDL3 significantly reduced neutral lipid content (Fig. 8C,
E); HDL3 modified for 15 min with 15-LO further decreased
cell lipid content (Fig 8D, E).
4. Discussion
Lipoproteins modification is usually regarded as a
deleterious process, which affects their physiological
properties, triggering events that can promote atherogenesis.
HDL modification impairs its ability to promote cholesterol
efflux from cultured cells, suggesting that changes in the
protein and/or lipid moiety alter the athero-protective role of
HDL [21–23,30]. Not all modification of HDL, however,
shift HDL towards a pro-atherogenic particle. Tyrosylation,
for instance, enhances the removal of cholesterol from
cultured fibroblasts and macrophages [42] and the admin-
istration of tyrosylated HDL to apo-E-deficient mice induces
a significant decrease of atherosclerotic lesions [43]. The
mechanism by which tyrosylated HDL exerts its protective
role seems to be independent of passive cholesterol
desorption from the cell membrane, suggesting a possible
involvement of ABCA1 activity [44]. These observations
suggest that lipoprotein modification does not always confer
pro-atherogenic properties. In the present work we show that
mild oxidative modification (enzymatic or non-enzymatic)
of HDL3 enhances its ability to induce cholesterol efflux
from cells and provides evidence that newly formed pre-β-
HDL3 are responsible for this effect through the interaction
with ABCA1.
Experimental evidence suggests that oxidative stress
represents a key factor in the initiation of vascular
dysfunctions associated with atherosclerosis. Both systemic
factors, such as hypercholesterolemia [45] and local factors,
such as activation of macrophages and T-cells, may
contribute to oxidative stress [26]; diet-induced atheroscle-
rosis in different animal models is related, in fact, to an
enhanced xanthine oxidase activity and ROS production
[45,46]. The tight regulation of both production and removal
of reactive oxygen species induces transient fluctuations in
oxidant levels modulating gene expression and thus,
metabolic switches [47]. Extracellular stimuli like angioten-
sin II or TNFα [48,49], or pathophysiological conditions
such as hypercholesterolemia can shift the balance to a pro-
oxidant state, resulting in a decreased activity of antioxidant
enzymes (SOD, catalase, GPx) and in lipoprotein modifica-
tion. Copper is normally tightly sequestered in biological
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 system and is not readily available as oxidation catalyst.
Nevertheless, pro-oxidant forms of copper may be present in
circulation and in artery wall of human atherosclerotic
lesions [50]. In addition, ROS may be generated through
processes mediated by different enzymes such as lipox-
ygenases [51]. Specifically, 15-lipoxygenase can induce
oxidative modification of LDL, rendering them pro-athero-
genic [29]. Experimental evidence support such pro-
atherogenic activity of this enzyme [52,53]. On the other
hand, data obtained with transgenic rabbits overexpressing
15-lipoxygenase in monocytes/macrophages suggest an anti-
atherogenic effect [32,33]. Thus, the enzyme may exhibit a
dual role in LDL metabolism during atherogenesis (pro- and
anti-atherogenic activity). Similarly, our previous results
[30] and the data presented in this study suggest a dual
activity of 15-lipoxygenase on HDL. In early stages of HDL
modification, production of pre-β-migrating particles might
result in an anti-atherogenic role, with an improvement of
HDL-mediated reverse cholesterol transport, thus resulting
in a reduced cellular cholesterol content. A crucial role for
the interaction between pre-β-migrating particles formed in
mild modified HDL3 and ABCA1 can be assumed, as
suggested by experiments using an ABCA1 inhibitor or
Tangier fibroblasts expressing a non-functional form of
ABCA1 [41]. At later time points, when HDL particles are
converted into more extensively modified species, the
cholesterol accepting properties are lost [30] and reverse
cholesterol transport is impaired. This effect may contribute
in vivo to the formation of lipid-laden foam cells.
The data obtained in the present study suggest also that
pre-β-migrating particles detected in mildly oxidized HDL3
were generated ex-novo from α-particles and did not derive
from a conformational change of apoA-I in the pre-β-HDL
already present in the lipoprotein preparation. This finding is
supported by the observation that oxidation of lipid-bound
apoA-I significantly decreases its stability [54]; destabilized
apoA-I can be readily released from HDL, providing a pool
of lipid-free/lipid-poor apoA-I that exhibits a pre-β electro-
phoretic mobility. When oxidation proceeds, apoA-I
becomes further oxidized, thus increasing the negative
particle charge, and this could explain the loss of pre-β-
migrating particles observed by agarose gel electrophoresis.
Moreover, an extensive HDL3 oxidation leads to an
increased particles size (not shown) with a reduced
ABCA1-mediated cholesterol efflux.
In hypercholesterolemic subjects plasma level of pre-β1-
HDL is increased [18,55]. Moreover, sera from patients with
lowHDL cholesterol, such as in hypertriglyceridemic, trigger
a significant increase in cholesterol efflux from J774 cells
overexpressing ABCA1, when compared to normolipidemic
controls [55]. This effect was attributed to the increased levels
of pre-β-HDL particles in hypertriglyceridemic serum. Since
hypercholesterolemia is associated with an increased oxida-
tive potential [45,56], the processes investigated here might
be of pathophysiological relevance in vivo, as our data
indicate that pre-β-migrating particles can be formed by mildoxidative modification of HDL3. Whether pre-β-particles
generated under our experimental conditions are structurally
related to those detected in hypercholesterolemic plasma
remains to be addressed. We can only suggest a common
ABCA1-mediated mechanism of cholesterol efflux.
Taken together these data are consistent with the
hypothesis that mild oxidative modification of HDL, which
leads to the formation of pre-β-HDL migrating particles,
might be considered an anti-atherogenic process enhancing
reverse cholesterol transport and thus, impairing intracellular
lipid deposition in peripheral cells. However, when oxidation
proceeds further, HDL lose their cholesterol effluxing
properties [30]. These results provide additional evidence
for the previous suggestion [57] that a low degree of
oxidation is needed for a balanced steady state of lipid
metabolism. Deviations in either direction might induce
cascades leading to intracellular lipid deposition. Moreover,
these results may also contribute to explain the clinical failure
of antioxidant therapy in cardiovascular disease [58–60].
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